Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Analyst Ratings for Edgewise Therapeutics | 1 | Benzinga.com | ||
EDGEWISE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Mi | Edgewise Therapeutics GAAP EPS of -$0.30 misses by $0.02 | - | Seeking Alpha | ||
Mi | Recap: Edgewise Therapeutics Q1 Earnings | - | Benzinga.com | ||
Mi | Edgewise Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
Mi | Edgewise Therapeutics, Inc. - 10-Q, Quaterly Report | - | SEC Filings | ||
24.02. | Edgewise Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
24.02. | Edgewise Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
24.02. | Edgewise Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.01. | Hot Stocks: Fed routes Bitcoin stocks; W, EPC move on analyst notes; EWTX data; BPMC management change | 1 | Seeking Alpha | ||
05.01. | EWTX, STXS, GOCO among mid-day movers | 1 | Seeking Alpha | ||
05.01. | Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study | - | Benzinga.com | ||
05.01. | Why Edgewise Therapeutics Is Rising In Pre-market? | 1 | RTTNews | ||
05.01. | Edgewise Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.12.21 | Edgewise and eFFECTOR recover from recent slump | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 152,45 | -0,13 % | InnoCan Pharma - Das Unternehmen mit dem "Magic Bullet" im 2,2-Billionen-USD-Markt? | ||
QIAGEN | 44,170 | +3,90 % | Qiagen holt Biotech-Managerin als zusätzliches Aufsichtsratsmitglied | DJ Qiagen holt Biotech-Managerin als zusätzliches Aufsichtsratsmitglied
FRANKFURT (Dow Jones)--Die Qiagen NV will ihren Aufsichtsrat auf acht von sieben Mitgliedern erweitern. Wie das Unternehmen... ► Artikel lesen | |
BEAM THERAPEUTICS | 35,450 | +12,75 % | Beam Therapeutics Inc. Q1 Loss decreases, beats estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for first quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 39,190 | +10,89 % | SpringWorks, Regeneron To Evaluate Nirogacestat In Combination With REGN5458 In Multiple Myeloma | WASHINGTON (dpa-AFX) - SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company, Tuesday said it has entered into a clinical trial collaboration and supply agreement... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 22,630 | +9,64 % | Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600 | NEW YORK, March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE: CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent... ► Artikel lesen | |
EVOTEC | 24,140 | +12,75 % | Heute bei Evotec Kasse machen? | Hochstimmung herrscht heute bei den Aktionären von Evotec. Derzeit notiert das Wertpapier mit rund drei Prozent im Gewinn. Damit valutiert der Titel nun bei 21,63 EUR. Evotec ist dadurch gewaltig im... ► Artikel lesen | |
TURNING POINT THERAPEUTICS | 32,600 | +11,15 % | Turning Point Therapeutics GAAP EPS of -$1.50 beats by $0.01, revenue of $0.43M | ||
ALLOGENE THERAPEUTICS | 7,230 | +3,73 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Named 2022 Bay Area "Best Place to Work" by San Francisco Business Times and Silicon Valley Business ... | ||
RELAY THERAPEUTICS | 17,580 | +11,83 % | Relay Therapeutics GAAP EPS of -$0.57 beats by $0.05, revenue of $0.42M | ||
ARVINAS | 43,130 | +6,65 % | GNS and Arvinas partner for neurodegenerative disease drug development | ||
KARUNA THERAPEUTICS | 103,90 | +3,99 % | Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss | ||
GINKGO BIOWORKS | 2,670 | +12,18 % | Looking Into Ginkgo Bioworks Holdings's Recent Short Interest | ||
ARCTURUS THERAPEUTICS | 16,980 | +15,43 % | Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M | ||
ZENTALIS PHARMACEUTICALS | 20,530 | +8,39 % | Zentalis Pharmaceuticals GAAP EPS of -$1.31 misses by $0.10 | ||
2SEVENTY BIO | 11,920 | +6,05 % | 2seventy bio GAAP EPS of -$3.20, revenue of $8.43M |